氨磺必利与利培酮治疗精神分裂症患者的对照研究

目的：比较氨磺必利与利培酮治疗精神分裂症患者疗效与不良反应。方法：140例符合中国精神障碍分类与诊断标准第3版精神分裂症诊断标准的患者随机分为两组，每组70例：分别给予氨磺必利与利培酮治疗8周，采用阳性与阴性量表（PANss）评定疗效，治疗中出现的症状量表（TESS）评定不良反应。结果：治疗8周后氨磺必利组治愈率34．3％，有效率77．1％，利培酮治愈率32．9％，有效率32．9％，两组疗效比较无显著性差异（P〉O．05）；氨磺必利组不良反应发生率41．43％，利培酮组发生率为45．7％，两组比较无显著性差异（P〉0．05）。结论：氨磺必利与利培酮治疗精神分裂症的疗效和不良反应相似，需根据患者具体情况选择合适的药物。

Comparison of efficacy and safety of Amisulpride and Risperidone in treating patients with schizophrenia

Objective：To compare the efficacy and safety between Amisulpride and Risperidone in treatment of schizophrenia. Methods. 140 patients with schizophrenia who met the schizophrenia criterion of Chinese classification of mental disorder were divided into two groups randomly and treated with Amisulpride and Risperidone for 8 weeks. The positive and negative scale （PANSS） and treatment emergent side effect scale （TESS） were used to evaluate the efficacy and adverse effect respectively. Results： The cure rate of Amisulpride group was 34.3% and efficacy rate was 77.1% after 8 weeks. While 32.9% and 75.7% in Risperidone group. There were no statistical different between two groups （ P 〉 0.05 ）. The incidence rate of adverse effect was 41.43% in Amisulpride group and that was 45.7% in Risperdone group, with statistical different between them （P 〉 0.05）. Conclusions： Amisulpride and Risperdone are similarly effective and adverse effect in the treatment of schizophrenia. We can choice suitable drug by patients 6ondition.